MSD TET ANTI TOX 50000IUIn

Target species Horse, sheep and dog. Indications for use Tetanus Antitoxin Behring is intended for prophylactic use in horses, sheep and dogs to reduce the risk of tetanus infection, as a result of accidental injury or as a preoperative precaution. After subcutaneous and intramuscular injection of Tetanus Antitoxin Behring, maximum serological titres can be expected approximately 2 days after administration. The titres slowly decrease with time, but the protective effect lasts for between 2 and 3 weeks. Tetanus Antitoxin Behring is intended for therapeutic use in horses and dogs to enhance recovery rates in animals showing clinical signs of tetanus, when combined with other treatments After intravenous or intramuscular injection to horses, serological titres associated with protection can be reached within one to four hours. After subarachnoidal injection effective titres in the central nervous system are reached straight after application. The duration of effective antibody titres has not been investigated in the central nervous system. The intravenous and subarachnoidal application routes are recommended for therapeutic use of Tetanus Antitoxin Behring in horses only. Contra-indications Administration to cats is contra-indicated. Cats are unable to metabolise the preservative phenol as rapidly as other species due to the absence of a specific enzyme. Special warnings for each target species After repeated administration at longer intervals sensitisation may occur, leading to hypersensitivity reactions/anaphylactic shock. Administering repeat doses at longer intervals is therefore not recommended. Especially if a (repeated) intravenous application is intended in heterologous animals a biological pre-testing (1 ml Tetanus Antitoxin Behring, subcutaneous, 30 - 40 minutes observation) should be performed. Special precautions for use None. Adverse reactions A transient local swelling may occur after vaccination. A transient rise in body temperature may occasionally occur on the day of application and the day after. In very rare cases, especially after repeated administration, hypersensitivity reactions may occur. Especially heterologous animals are susceptible (see Section “Special warnings for each target species”). It has been concluded from studies that the product is unlikely to exacerbate the disease when it is administered to horses affected with clinical tetanus, with doses of 20,000 to 50,000 IU, administered by the intramuscular, subcutaneous or intravenous routes, if necessary repeated at intervals over the space of a few days, or by injection into the subarachnoid space. Use during pregnancy, lactation or lay The safe use of Tetanus Antitoxin Behring during pregnancy and lactation has not specifically been assessed. However, with regard to use in horses, on the basis of experience from field use in mares and from published data employing the administration of a different tetanus hyperimmune serum in pregnant mares it is concluded that it is unlikely to cause any reaction other than that described in section "Adverse reactions". Interactions Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Equilis Te and Equilis Prequenza Te (for proper use, refer to the package leaflets). No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Vat Rate: 20%